Humana: Up 13% In A Week, Will HUM Stock Rally Continue?
Humana (NYSE: HUM) is currently riding a wave of positive momentum. The stock has been on a five-day continuous winning streak, delivering cumulative gains of 13% and adding approximately $4.0 billion in value.
Humana loses challenge to 2025 Medicare Advantage ratings
A U.S. judge on Tuesday rejected Humana's bid to challenge the Centers for Medicare & Medicaid Services' 2025 ratings for its Medicare Advantage programs, which could cost the company millions in bonus payments from the government.
Why Humana (HUM) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Humana provides a peak into its Medicare Advantage plan ratings, and the stock jumps
Humana's stock spiked after the health insurer disclosed some findings from the government's Star Ratings for its 2026 Medicare Advantage plans.
Humana Benefits From Rising Premiums Amid High Benefit Ratio
HUM gains from rising premiums, Medicare growth and CenterWell expansion, but faces pressure from high benefit ratios and costs.
Is Humana (HUM) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Is Humana (HUM) Up 19.2% Since Last Earnings Report?
Humana (HUM) reported earnings 30 days ago. What's next for the stock?
Here's Why Humana (HUM) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Humana, DrFirst Ties Up to Boost Statin Use in High-Risk Patients
HUM partners with DrFirst to increase statin use in high-risk patients with diabetes and cardiovascular disease, aiming to close care gaps.
Here's Why Humana (HUM) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Humana (HUM) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
HUM Misses Q2 Earnings on Higher Benefit Costs, Ups '25 EPS View
Humana's Q2 earnings fall year over year on a declining membership base. Notably, 2025 adjusted EPS is currently forecasted at around $17.00, up from the earlier view of around $16.25.
